{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T20:47:37Z","timestamp":1767905257262,"version":"3.49.0"},"reference-count":43,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010817","name":"Stiftelsen Kronprinsessan Margaretas Arbetsn\u00e4mnd f\u00f6r Synskadade","doi-asserted-by":"publisher","award":["2019\u2010016"],"award-info":[{"award-number":["2019\u2010016"]}],"id":[{"id":"10.13039\/100010817","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Ophthalmologica"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>The primary objective was to evaluate prescribing trends for topical ocular hypotensive treatment in the Nordic region during the last decade and, by population projections, estimate the glaucoma burden in 2040. A secondary objective was to analyse national variations in prescription patterns across the Nordic region.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective analysis of national pharmacy data between 2008 and 2017 on the dispensation of topical ocular hypotensive treatment in the Nordic region was performed. Predictions of the glaucoma burden in 2040 were calculated from official population projections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The total number of patients with ocular hypotensive treatment in the Nordic region increased from 346\u2009000 to 418\u2009000 (21%) between 2008 and 2017. The number of patients with ocular hypotensive treatment in the age group of 50\u2009years and older increased from 3.6% to 3.9%. The daily defined dose (DDD) per patient and day during the study period increased from 1.22 to 1.26. Adjusted for beta\u2010blocker combinations, the same value increased from 1.49 to 1.67. Across the Nordic countries, Finland had almost twice as many DDD per patient and day in 2017 (2.1) compared with Iceland (1.1). Between 2008 and 2017, the annual treatment cost for ocular hypotensive treatment in the Nordic region decreased from 96 million to 87 million Euro (\u22129%). In 2040, the number of patients with ocular hypotensive treatment in the Nordic region is estimated to 633\u2009000 individuals (+51% compared with 2017).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The study revealed an increased use of glaucoma medications in the Nordic region the last decade. This was mainly caused by an increased number of patients with ocular hypotensive treatment, but also because of a more intensive treatment. Marked national differences were detected. Due to the introduction of generic medications, the total cost for ocular hypotensive treatment did however decrease during the last decade. In 2040, the current number of individuals with ocular hypotensive treatment is estimated to have increased with an additional 50% due to a growing number of ageing individuals. This will lead to higher costs, not only for medications but also for diagnosing, monitoring and other aspects of glaucoma care.<\/jats:p><\/jats:sec>","DOI":"10.1111\/aos.14848","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T09:54:07Z","timestamp":1615802047000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The future is old \u2013 Patients with topical ocular hypotensive treatment in the Nordic region between 2008 and 2017 with projections for 2040"],"prefix":"10.1111","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0185-4326","authenticated-orcid":false,"given":"Tomas","family":"Bro","sequence":"first","affiliation":[{"name":"Department of Ophthalmology Eksj\u00f6 Sweden"},{"name":"Section\u00a0for Ophthalmology Department of Clinical Sciences Lund University Lund Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4973-3566","authenticated-orcid":false,"given":"Kerstin","family":"Wickstr\u00f6m","sequence":"additional","affiliation":[{"name":"Icelandic Medicines Agency Reykjavik Iceland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3597-4740","authenticated-orcid":false,"given":"Christina","family":"Lind\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Ophthalmology Ume\u00e5 University Ume\u00e5 Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0420.2005.00513.x"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0420.2001.079001002.x"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2014.114"},{"key":"e_1_2_5_5_1","unstructured":"Danish Health Data Authority.Medstat.dk. Available at:http:\/\/www.medstat.dk\/. (Accessed on 07 Jun 2019)."},{"key":"e_1_2_5_6_1","unstructured":"Danish Medicines Agency(2020):Reimbursement thresholds. Available at:https:\/\/laegemiddelstyrelsen.dk\/en\/reimbursement\/calculate\u2010reimbursement\/reimbursement\u2010thresholds\/. (Accessed on 19 May 2020)."},{"key":"e_1_2_5_7_1","first-page":"140","article-title":"European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition \u2010 Chapter 3: Treatment principles and options Supported by the EGS. Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 3 Treatment principles and options","volume":"101","author":"EGS","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"e_1_2_5_8_1","unstructured":"Felleskatalogen AS(2020):Felleskatalogen: Medisiner og refusjon. Available at:https:\/\/www.felleskatalogen.no\/medisin\/nyttig\u2010om\/refusjon. (Accessed on 29 Sep 2020)."},{"key":"e_1_2_5_9_1","volume-title":"Finnish Statistics on Medicines 2017","author":"Finnish Medicines Agency Fimea and Social Insurance Institution","year":"2018"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62111-5"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32213-X"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.1989.tb00754.x"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12141"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.01.043"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.10.1268"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010429"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-019-0656-z"},{"key":"e_1_2_5_18_1","unstructured":"Icelandic Health Insurance Centre(2019):Reimbursement thresholds. Available at:https:\/\/www.sjukra.is\/english\/social\u2010insurance\u2010in\u2010iceland\/medicine\/. (Accessed on 10 Jun 2020)."},{"key":"e_1_2_5_19_1","unstructured":"Icelandic Medicines Agency Statistics.https:\/\/www.ima.is\/publications\/statistics\/(Accessed on 07 Jun 2019)."},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2005.076117"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132048"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0420.2005.00560.x"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6702593"},{"key":"e_1_2_5_24_1","unstructured":"National Board of Health and Welfare.Statistikdatabas f\u00f6r L\u00e4kemedel. Available at:https:\/\/sdb.socialstyrelsen.se\/if_lak\/val.aspx. (Accessed on 07 Jun 2019)."},{"key":"e_1_2_5_25_1","unstructured":"Nordic Council of Ministers(2018):State of the Nordic Region 2018. Rosendahls."},{"key":"e_1_2_5_26_1","unstructured":"Norwegian Institute of Public Health.Reseptregisteret. Available at:http:\/\/www.reseptregisteret.no\/. (Accessed on 07 Jun 2019)."},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S239772"},{"key":"e_1_2_5_28_1","unstructured":"Socialstyrelsen(2019):Statistikdatabas f\u00f6r operationer. Available at: https:\/\/sdb.socialstyrelsen.se\/if_ope\/val.aspx. (Accessed on 05 Nov 2020)."},{"key":"e_1_2_5_29_1","unstructured":"Statistics Denmark.Befolkningsfremskrivning 2019 for hele landet efter herkomst k\u00f8n og alder. Available at:https:\/\/www.dst.dk\/da(Accessed on 23 Apr 2020)."},{"key":"e_1_2_5_30_1","unstructured":"Statistics Finland.Befolkningsprognos 2019: Befolkning efter \u00e5lder k\u00f6n och omr\u00e5de. Available at:http:\/\/stat.fi\/index_sv.html. (Accessed on 23 Apr 2020)."},{"key":"e_1_2_5_31_1","unstructured":"Statistics Iceland.Population projection by age and sex. Available at:https:\/\/statice.is\/. (Accessed on 23 Apr 2020)."},{"key":"e_1_2_5_32_1","unstructured":"Statistics Norway.Framskrevet folkemengde 1. januar etter kj\u00f8nn alder innvandringskategori og landbakgrunn. Available at:https:\/\/www.ssb.no\/. (Accessed on 23 Apr 2020)."},{"key":"e_1_2_5_33_1","unstructured":"Statistics Sweden.Befolkningsframskrivningar \u2010Aktuella framskrivningar \u2010Folkm\u00e4ngd efter f\u00f6delseregion \u00e5lder och k\u00f6n. Available at:https:\/\/www.scb.se\/. (Accessed on 23 Apr 2020)."},{"key":"e_1_2_5_34_1","doi-asserted-by":"crossref","unstructured":"Statistics Sweden(2018):Sveriges framtida befolkning 2018\u20132070.","DOI":"10.1787\/int_trade-v2018-1-34-en"},{"key":"e_1_2_5_35_1","unstructured":"Sveriges Riksbank(2019):Annual average exchange rates. Available at:https:\/\/www.riksbank.se\/en\u2010gb\/statistics\/search\u2010interest\u2010\u2010exchange\u2010rates\/annual\u2010average\u2010exchange\u2010rates\/. (Accessed on 11 Aug 2019)."},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.05.013"},{"key":"e_1_2_5_37_1","unstructured":"The Dental and Pharmaceutical Benefits Agency(2019):International price comparison 2018."},{"key":"e_1_2_5_38_1","unstructured":"The Dental and Pharmaceutical Benefits Agency(2020):S\u00e5 fungerar h\u00f6gkostnadsskyddet. Available at:https:\/\/www.tlv.se\/lakemedel\/hogkostnadsskyddet\/sa\u2010fungerar\u2010hogkostnadsskyddet.html. (Accessed on 29 Sep 2020)."},{"key":"e_1_2_5_39_1","unstructured":"The Social Insurance Institution of Finland.Finnish statistics on medicines. Available at:https:\/\/www.kela.fi\/web\/en\/statistical\u2010publications_finnish\u2010statistics\u2010on\u2010medicines. (Accessed on 07 Jun 2019)."},{"key":"e_1_2_5_40_1","first-page":"187","article-title":"Glaucomatous visual field loss in eyes undergoing first trabeculectomy in Iceland","volume":"106","author":"Tryggvadottir EB","year":"2020","journal-title":"Laeknabladid"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1475-1313.2003.00104.x"},{"key":"e_1_2_5_42_1","unstructured":"UusitaloH SiitonenA&OjamoM(2014):Glaucoma patients in Finland and their visual prognosis. Data of the Finnish Register of Visual Impairment during the 30 years 11th EGS Conferance. Nice."},{"key":"e_1_2_5_43_1","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology(2018):Guidelines for ATC classification and DDD assignment 2019. Oslo Norway."},{"key":"e_1_2_5_44_1","unstructured":"World Health Organization(2017):Global data on visual impairments 2010."}],"container-title":["Acta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.14848","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/aos.14848","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.14848","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T02:54:15Z","timestamp":1705892055000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/aos.14848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1111\/aos.14848"],"URL":"https:\/\/doi.org\/10.1111\/aos.14848","archive":["Portico"],"relation":{},"ISSN":["1755-375X","1755-3768"],"issn-type":[{"value":"1755-375X","type":"print"},{"value":"1755-3768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,15]]},"assertion":[{"value":"2020-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}